Design Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Design Therapeutics (DSGN).

Price Target Range — 8 Quarters

Analyst Consensus — 7 Analysts

6Buy

1Hold

Consensus RatingOutperform# Analysts7Avg. Consensus PT$16Upside to Avg. PT+51.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 2, 2026	Wells Fargo	Tianqi Hang	Initiate	Overweight	$26
May 4, 2026	Oppenheimer	Kostas Biliouris	PT Raise	Outperform	$18→$21
Mar 16, 2026	Jefferies	Faisal Khurshid	Initiate	Buy	$15
Mar 10, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$13→$14
Jan 7, 2026	Oppenheimer	Trevor Allred	Initiate	Outperform	$18
Dec 3, 2025	Leerink Partners	Joseph Schwartz	Upgrade	Market Perform→Outperform	$7→$14
Nov 20, 2025	RBC Capital	Leonid Timashev	Upgrade	Sector Perform→Outperform	$6→$13
Nov 6, 2025	RBC Capital	Leonid Timashev	PT Raise	Sector Perform	$5→$6
Aug 6, 2024	RBC Capital	Leonid Timashev	Maintained	Sector Perform	$4
May 7, 2024	Piper Sandler	Yasmeen Rahimi	Upgrade	Neutral→Overweight	$6→$12
Mar 20, 2024	RBC Capital	Leonid Timashev	Maintained	Sector Perform	$4
Mar 20, 2024	Wedbush	Laura Chico	Maintained	Neutral	$5
Nov 14, 2023	RBC Capital	Leonid Timashev	PT Cut	Sector Perform	$7→$4

Analyst Ratings News

PRO
Wells Fargo Initiates Coverage On Design Therapeutics with Overweight Rating, Announces Price Target of $26

Wells Fargo analyst Tianqi Hang initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Overweight rating and announces Price Target of $26.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Design Therapeutics, Raises Price Target to $21

Oppenheimer analyst Kostas Biliouris maintains Design Therapeutics (NASDAQ:DSGN) with a Outperform and raises the price target from $18 to $21.

Benzinga Newsdesk

PRO
Jefferies Initiates Coverage On Design Therapeutics with Buy Rating, Announces Price Target of $15

Jefferies analyst Faisal Khurshid initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Buy rating and announces Price Target of $15.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Design Therapeutics, Raises Price Target to $14

RBC Capital analyst Leonid Timashev maintains Design Therapeutics (NASDAQ:DSGN) with a Outperform and raises the price target from $13 to $14.

Benzinga Newsdesk

PRO
Oppenheimer Initiates Coverage On Design Therapeutics with Outperform Rating, Announces Price Target of $18

Oppenheimer analyst Trevor Allred initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Outperform rating and announces Price Target of $18.

Benzinga Newsdesk

PRO
Leerink Partners Upgrades Design Therapeutics to Outperform, Raises Price Target to $14

Leerink Partners analyst Joseph Schwartz upgrades Design Therapeutics (NASDAQ:DSGN) from Market Perform to Outperform and raises the price target from $7 to $14.

Benzinga Newsdesk

Design Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Design Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Wells Fargo Initiates Coverage On Design Therapeutics with Overweight Rating, Announces Price Target of $26

PRO
Oppenheimer Maintains Outperform on Design Therapeutics, Raises Price Target to $21

PRO
Jefferies Initiates Coverage On Design Therapeutics with Buy Rating, Announces Price Target of $15

PRO
RBC Capital Maintains Outperform on Design Therapeutics, Raises Price Target to $14

PRO
Oppenheimer Initiates Coverage On Design Therapeutics with Outperform Rating, Announces Price Target of $18

PRO
Leerink Partners Upgrades Design Therapeutics to Outperform, Raises Price Target to $14

People Also Watch

People Also Watch

Design Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Design Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWells Fargo Initiates Coverage On Design Therapeutics with Overweight Rating, Announces Price Target of $26

PROOppenheimer Maintains Outperform on Design Therapeutics, Raises Price Target to $21

PROJefferies Initiates Coverage On Design Therapeutics with Buy Rating, Announces Price Target of $15

PRORBC Capital Maintains Outperform on Design Therapeutics, Raises Price Target to $14

PROOppenheimer Initiates Coverage On Design Therapeutics with Outperform Rating, Announces Price Target of $18

PROLeerink Partners Upgrades Design Therapeutics to Outperform, Raises Price Target to $14

People Also Watch

People Also Watch

PRO
Wells Fargo Initiates Coverage On Design Therapeutics with Overweight Rating, Announces Price Target of $26

PRO
Oppenheimer Maintains Outperform on Design Therapeutics, Raises Price Target to $21

PRO
Jefferies Initiates Coverage On Design Therapeutics with Buy Rating, Announces Price Target of $15

PRO
RBC Capital Maintains Outperform on Design Therapeutics, Raises Price Target to $14

PRO
Oppenheimer Initiates Coverage On Design Therapeutics with Outperform Rating, Announces Price Target of $18

PRO
Leerink Partners Upgrades Design Therapeutics to Outperform, Raises Price Target to $14